What it is used for

COPD,Breo Ellipta is indicated for symptomatic treatment of patients with COPD with a FEV1 <70% predicted normal (post-bronchodilator) in patients with an exacerbation history despite regular bronchodilator therapy.,Breo Ellipta is not indicated for the initiation of bronchodilator therapy in COPD.,Asthma,Breo Ellipta is indicated in the regular treatment of moderate to severe asthma in patients who require a medium to high dose inhaled corticosteroid combined with a long-acting beta-2-agonist.,Vilanterol, an active ingredient in Breo Ellipta, is a long-acting beta-2-agonist (LABA). A class effect of all LABAs can be an increased risk of asthma death (see Precautions).

How to take it

The way to take this medicine is: Inhalation.

• Store below 30 degrees Celsius
• See Product information for shelf life
• Shelf lifetime is 2 Years.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.

Visual appearance

A plastic inhaler with light grey body, pale blue mouthpiece cover and a dose counter, containing two strips of blisters each containing a white powder

Do I need a prescription?

This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine. open tool tip to find out more

Is this medicine subsidised?

This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March 1, 2023. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.

Pregnant or planning a pregnancy?

For the active ingredient fluticasone furoate + vilanterol

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.